424 related articles for article (PubMed ID: 28438129)
21. Changes in the size and number of skin lesions in PB leprosy on treatment and follow-up.
Rao PN; Suneetha S; Pratap DV
Lepr Rev; 2011 Sep; 82(3):244-52. PubMed ID: 22125932
[TBL] [Abstract][Full Text] [Related]
22. A 6 week quadruple drug regimen for the treatment of multibacillary leprosy.
Pattyn S; Grillone S
Lepr Rev; 2000 Mar; 71(1):43-6. PubMed ID: 10820986
[No Abstract] [Full Text] [Related]
23. Two microbiological relapses in a patient with lepromatous leprosy.
Chakma JK; Girdhar A; Natrajan M; Kumar A; Girdhar BK
Lepr Rev; 2008 Sep; 79(3):331-4. PubMed ID: 19009984
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of multidrug therapy in paucibacillary leprosy in Singapore.
Lim JT; Tan T
Lepr Rev; 1993 Jun; 64(2):136-42. PubMed ID: 8341116
[TBL] [Abstract][Full Text] [Related]
25. Developing new MDT regimens for MB patients; time to test ROM 12 month regimens globally.
Lockwood DN; Cunha Mda G
Lepr Rev; 2012 Sep; 83(3):241-4. PubMed ID: 23356024
[No Abstract] [Full Text] [Related]
26. Daily multidrug therapy for leprosy; results of a fourteen-year experience.
de Carsalade GY; Wallach D; Spindler E; Pennec J; Cottenot F; Flageul B
Int J Lepr Other Mycobact Dis; 1997 Mar; 65(1):37-44. PubMed ID: 9207752
[TBL] [Abstract][Full Text] [Related]
27. Type 1 reaction in leprosy: a model for a better understanding of tissue immunity under an immunopathological condition.
Andrade PR; Pinheiro RO; Sales AM; Illarramendi X; Barbosa MG; Moraes MO; Jardim MR; Nery JA; Sampaio EP; Sarno EN
Expert Rev Clin Immunol; 2015 Mar; 11(3):391-407. PubMed ID: 25666357
[TBL] [Abstract][Full Text] [Related]
28. Study of multidrug therapy in paucibacillary leprosy.
Kar PK; Sohi AS
J Indian Med Assoc; 1989 Feb; 87(2):34-6. PubMed ID: 2674283
[TBL] [Abstract][Full Text] [Related]
29. Clinical pilot study: Clarithromycin efficacy in multibacillary leprosy therapy.
Gunawan H; Sasmojo M; Putri HE; Avriyanti E; Hindritiani R; Suwarsa O
Int J Mycobacteriol; 2018; 7(2):152-155. PubMed ID: 29900892
[TBL] [Abstract][Full Text] [Related]
30. Relapses in leprosy patients treated with rifampicin plus dapsone after varying periods of dapsone monotherapy.
Li HY; Ran SP; Weng XM; Li TG; Deng XH; Li FT
Indian J Lepr; 2001; 73(1):1-10. PubMed ID: 11326592
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness of multidrug therapy in multibacillary leprosy: a long-term follow-up of 34 multibacillary leprosy patients treated with multidrug regimens till skin smear negativity.
Shaw IN; Christian M; Jesudasan K; Kurian N; Rao GS
Lepr Rev; 2003 Jun; 74(2):141-7. PubMed ID: 12862255
[TBL] [Abstract][Full Text] [Related]
32. Potential Role of CXCL10 in Monitoring Response to Treatment in Leprosy Patients.
Ferreira H; Mendes MA; de Mattos Barbosa MG; de Oliveira EB; Sales AM; Moraes MO; Sarno EN; Pinheiro RO
Front Immunol; 2021; 12():662307. PubMed ID: 34354699
[TBL] [Abstract][Full Text] [Related]
33. Leprosy in a renal transplant recipient: review of the literature.
Guditi S; Ram R; Ismal KM; Sahay M; Dakshinamurthy KV; Girish N; Prasad N
Transpl Infect Dis; 2009 Dec; 11(6):557-62. PubMed ID: 19656347
[TBL] [Abstract][Full Text] [Related]
34. Comparison of PCR mediated amplification of DNA and the classical methods for detection of Mycobacterium leprae in different types of clinical samples in leprosy patients and contacts.
Torres P; Camarena JJ; Gomez JR; Nogueira JM; Gimeno V; Navarro JC; Olmos A
Lepr Rev; 2003 Mar; 74(1):18-30. PubMed ID: 12669929
[TBL] [Abstract][Full Text] [Related]
35. HLA and leprosy in the pre and postgenomic eras.
Geluk A; Ottenhoff TH
Hum Immunol; 2006 Jun; 67(6):439-45. PubMed ID: 16728267
[TBL] [Abstract][Full Text] [Related]
36. Leprosy.
Marcos LA; Conerly S; Walker S
Am J Trop Med Hyg; 2014 Aug; 91(2):216. PubMed ID: 25100789
[No Abstract] [Full Text] [Related]
37. [Leprosy].
Ishii N; Sasaki S
Nihon Rinsho; 2003 Feb; 61 Suppl 2():531-5. PubMed ID: 12722275
[No Abstract] [Full Text] [Related]
38. In situ T regulatory cells and Th17 cytokines in paired samples of leprosy type 1 and type 2 reactions.
Costa MB; Hungria EM; Freitas AA; Sousa ALOM; Jampietro J; Soares FA; Stefani MMA
PLoS One; 2018; 13(6):e0196853. PubMed ID: 29883464
[TBL] [Abstract][Full Text] [Related]
39. Drug resistant-Mycobacterium leprae--results of mouse footpad studies from a laboratory in south India.
Ebenezer GJ; Norman G; Joseph GA; Daniel S; Job CK
Indian J Lepr; 2002; 74(4):301-12. PubMed ID: 12624978
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of anti-bacterial activity of Rifapentine, Clarithromycin, Minocycline, Moxifloxacin, Ofloxacin and their combinations in Murine Model of Rifampicin Resistant Leprosy.
Joseph P; Ponnaiya J; Das M; Chaitanya VS; Arumugam S; Ebenezer M
Indian J Lepr; 2016; 88(3):147-58. PubMed ID: 30207440
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
